Bridgewater Associates LP Boosts Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Bridgewater Associates LP increased its position in Lantheus Holdings, Inc. (NASDAQ:LNTHGet Rating) by 11.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 106,684 shares of the medical equipment provider’s stock after buying an additional 10,701 shares during the period. Bridgewater Associates LP’s holdings in Lantheus were worth $7,044,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in LNTH. Truist Financial Corp bought a new stake in Lantheus during the first quarter worth approximately $283,000. Mutual of America Capital Management LLC increased its stake in Lantheus by 5.5% during the first quarter. Mutual of America Capital Management LLC now owns 9,754 shares of the medical equipment provider’s stock worth $539,000 after acquiring an additional 505 shares during the last quarter. State of New Jersey Common Pension Fund D bought a new stake in Lantheus during the first quarter worth approximately $4,828,000. Versor Investments LP bought a new stake in Lantheus during the first quarter worth approximately $332,000. Finally, ClariVest Asset Management LLC bought a new stake in Lantheus during the first quarter worth approximately $1,128,000. 98.14% of the stock is owned by institutional investors.

Lantheus Stock Up 1.5 %

Shares of NASDAQ:LNTH opened at $58.76 on Thursday. Lantheus Holdings, Inc. has a 52-week low of $23.51 and a 52-week high of $87.47. The stock has a market cap of $4.04 billion, a P/E ratio of 39.44 and a beta of 0.79. The business’s 50 day moving average is $67.85 and its 200 day moving average is $70.15. The company has a quick ratio of 1.98, a current ratio of 2.13 and a debt-to-equity ratio of 0.24.

Lantheus (NASDAQ:LNTHGet Rating) last announced its quarterly earnings data on Thursday, November 3rd. The medical equipment provider reported $0.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.75 by $0.15. Lantheus had a return on equity of 37.77% and a net margin of 13.35%. The company had revenue of $239.29 million for the quarter, compared to analysts’ expectations of $228.52 million. Sell-side analysts predict that Lantheus Holdings, Inc. will post 3.51 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. SVB Leerink upped their target price on Lantheus from $110.00 to $120.00 and gave the company an “outperform” rating in a research note on Tuesday, November 15th. Mizuho assumed coverage on Lantheus in a research note on Wednesday, October 12th. They set a “buy” rating and a $105.00 target price on the stock. StockNews.com raised Lantheus from a “hold” rating to a “buy” rating in a research note on Friday, November 4th. Jonestrading assumed coverage on Lantheus in a research note on Thursday, October 6th. They set a “buy” rating and a $104.00 target price on the stock. Finally, B. Riley reaffirmed a “buy” rating on shares of Lantheus in a research note on Thursday, August 25th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, Lantheus has a consensus rating of “Buy” and a consensus price target of $102.80.

Insider Buying and Selling

In related news, CAO Andrea Sabens sold 386 shares of the stock in a transaction that occurred on Thursday, September 15th. The stock was sold at an average price of $85.83, for a total value of $33,130.38. Following the transaction, the chief accounting officer now owns 62,390 shares of the company’s stock, valued at $5,354,933.70. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Lantheus news, Director Brian A. Markison sold 41,812 shares of the company’s stock in a transaction on Thursday, September 8th. The stock was sold at an average price of $84.24, for a total transaction of $3,522,242.88. Following the completion of the sale, the director now owns 32,608 shares in the company, valued at $2,746,897.92. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CAO Andrea Sabens sold 386 shares of the company’s stock in a transaction on Thursday, September 15th. The stock was sold at an average price of $85.83, for a total value of $33,130.38. Following the sale, the chief accounting officer now owns 62,390 shares of the company’s stock, valued at approximately $5,354,933.70. The disclosure for this sale can be found here. Insiders have sold a total of 68,530 shares of company stock valued at $5,187,928 over the last quarter. 1.60% of the stock is owned by corporate insiders.

About Lantheus

(Get Rating)

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors.

Featured Stories

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTHGet Rating).

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.